bluebird bio, Inc.
NKG2D DARIC RECEPTORS

Last updated:

Abstract:

The present disclosure provides improved compositions for adoptive T cell therapies targeting NKG2D ligands for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Status:
Application
Type:

Utility

Filling date:

14 Dec 2018

Issue date:

5 Aug 2021